Troutman Pepper Advises Center for Breakthrough Medicines in $350M Investment from SK Inc.

PHILADELPHIA – Troutman Pepper client Center for Breakthrough Medicines Holdings, LLC (CBM) has received $350 million in equity financing from an affiliate of SK Inc., the second largest conglomerate in South Korea. CBM is partnering with SK to create the world’s largest end-to-end cell and gene therapy contract development and manufacturing organization (CDMO). Read CBM’s press release about the partnership.

CBM offers fully integrated, bench to bedside, pre-clinical through commercial manufacturing capabilities including, process development, plasmid DNA, viral vector manufacturing, cell banking, cell processing, and a full suite of complimentary testing and analytic capabilities.

The Troutman Pepper team advising CBM in the financing was led by Rachael Bushey and Chris Miller, and included Saba Ashraf, Allison Nicklin, Stephen Fox, Roe Granger, Neil Doogan, Michael Crumbock, Susan Lessack, Joseph Harrington, Dan Scolnick, and Judy O’Grady.

Health sciences is a core practice at Troutman Pepper. The firm has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical and medical device developers and manufacturers; physicians, hospitals and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including construction, energy, finance, health sciences, insurance, private equity, real estate, and technology, among others. Learn more at troutman.com.